Physician profile
Michael Ohebshalom
NPI 1568599447
$1,751.62
in general payments reported to CMS, 2019-2025
19 companies · $709 in 2025
The $709 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $95.82 · 2020: $42.68 · 2022: $110 · 2023: $526 · 2024: $268 · 2025: $709.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,503.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,503.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $582.79 | 2023-2025 | Gemtesa, Orgovyx |
| Janssen Biotech, INC. | $150.73 | 2023-2025 | Carvykti, Rybrevant, Erleada |
| Teleflex LLC | $148.27 | 2025 | Barrigel |
| Astellas Pharma US INC | $138.42 | 2022-2024 | Myrbetriq |
| Abbott Laboratories | $125.00 | 2023 | Freestyle Libre 3 |
| Progenics Pharmaceuticals, INC. | $125.00 | 2023 | Pylarify |
| Boston Scientific Corporation | $95.82 | 2019 | |
| Ferring Pharmaceuticals INC. | $70.58 | 2024-2025 | Adstiladrin |
| Coloplast Corp | $45.62 | 2025 | |
| Allergan, INC. | $42.68 | 2020 | |
| Urovant Sciences INC | $39.93 | 2022 | |
| Verity Pharmaceuticals INC. | $39.11 | 2023-2025 | Trelstar |
| Myriad Genetic Laboratories, INC. | $31.70 | 2025 | Myrisk |
| Civco Medical Instruments | $28.17 | 2025 | |
| Pfizer INC. | $25.05 | 2023 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $18.58 | 2025 | Interstim |
| Accord Healthcare, INC. | $16.00 | 2025 | |
| Myovant Sciences INC. | $14.86 | 2022 | |
| Abbvie INC. | $13.31 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Ohebshalom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.